New long-acting drugs to prevent migraines can cut the number and extremity of attacks, two clinical studies show.
Two studies of these medicines found that the drugs can cut the frequency of the well-known painful headaches. These designer drugs offer a Migraine suffers a new hope.
As a part of the treatment, the injection blocks brain molecules linked to migraine. The injection can be delivered at home and this will be the first new protective therapy in 20 years. This will be the start of a new change and can halve the length of attacks.
Erenumab, a laboratory-made antibody can block a neural brain pathway called CGRP, and can be sue to prevent migraine attacks.
“It clearly shows that blocking this pathway can reduce the impact of a migraine,” said Dr. Peter Goadsby, Professor of Neurology at King’s College London, who led the Phase III clinical trial.
The treatment uses antibodies to alter chemicals’ activity in the brain. Each year in Britain around 8.5 million people suffers from migraines, and in the UK, there is every day 200,000 attacks.
The charity Migraine Action’s Chief Executive, Simon Evans said, “Migraine is too often trivialized as just a headache when, in reality, it can be a debilitating, chronic condition that can destroy lives.”
Migraines are characterized by an extreme beating headache, nausea, low energy, sensitivity to light and noise, vomiting, and visual disturbances. Attacks can send from four to 72 hours.
Therefore, the treatment to prevent migraine attacks is necessary and Evans hopes that this new drug will mark the start of real change.